Pheast Therapeutics
Redwood City, US · Founded 2020 · Delaware corporation · 2 known investors
Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute. The company focuses on translating scientific discoveries into clinical therapies for patients.
Founders & leadership
IW
Irv WeissmanCofounder, Scientific Advisor, Board Director
RM
Ravi MajetiCofounder, Scientific Advisor, Board Observer
AB
Amira BarkalPrincipal Founder, Scientific Advisor, Board Director30 Under 30 2023
RM
Roy MauteCofounder & Chief Executive Officer
JV
Jacob VogelsteinDirector
SG
Steven GillisDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$24.6MraisedOct 2025 · 7 investors · Other TechnologyRule 506(b)
▶$24.6MraisedOct 2025 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Irving WeissmanDirector
- Roy MauteExecutive Officer, Director
- Raphael RousseauExecutive Officer
- Steven GillisDirector
- Jacob VogelsteinDirector
- Amira BarkalDirector
- Thomas MartyExecutive Officer
- Offering amount
- $40M
- Amount sold
- $24.6M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$75.3MraisedApr 2025 · 7 investors · Other TechnologyRule 506(b)
▶$75.3MraisedApr 2025 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Amira BarkalDirector
- Roy MauteExecutive Officer, Director
- Jacob VogelsteinDirector
- Irving WeissmanDirector
- Steven GillisDirector
- Offering amount
- $75.3M
- Amount sold
- $75.3M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Pheast Therapeutics Raises $76M in Series A Fundingfinsmes.com · 2022
- Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancerprnewswire.com · 2022